Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
In development
Reference number: GID-TA11386
Expected publication date: TBC
The committee meeting planned for 4 December 2024 will not go ahead. After considering the comments received on the External Assessment Group’s (EAG) report, NICE has decided to restart the evidence critique stage, and has asked Newcastle EAG to produce a new report. This work is expected to be completed by the end of May 2025. We therefore anticipate that a first committee discussion will now be September 2025. Access to treatments will continue while the appraisal is ongoing for people starting the treatments as well as those already taking the treatments.